Angion Biomedica Pulls The Plug On Another Kidney Disease Trial - Read Why

  • Angion Biomedica Corp ANGN has discontinued the JUNIPER Phase 2 trial of ANG-3070, an oral tyrosine kinase inhibitor, in primary proteinuric kidney diseases, specifically focal segmental glomerulosclerosis and immunoglobulin A nephropathy. 
  • The trial began enrolling patients in December 2021.
  • A reassessment was conducted following a potential safety signal of an unexpected and substantial decline in kidney function in a patient in the trial's drug treatment arm.
  • Related: Angion Biomedica Is 'Better Positioned' Than Peers Despite Trial Failure, HC Wainwright Thinks So
  • "Based on our ongoing analysis of the risk/benefit profile of ANG-3070 in patients with primary proteinuric kidney disease, we believe it to be in the best interest of patients to discontinue our Phase 2 JUNIPER study at this time..," stated CEO Jay Venkatesan.
  • Angion expects to report more than $60 million in cash and cash equivalents at the end of Q2.
  • In April, the company decided to discontinue the development of ANG-3777 after disappointing data.
  • Price Action: ANGN shares closed 18.7% lower at $1.39 during after-hours trading on Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!